Recombinant Escherichia coli biotransformation of biliverdin to synthesize bilirubin.

Yue Zhang, Haoni Luan, Wenhan Qiu, Wei Xu, Wei Feng, Fei Wang, Peng Song

Abstract read

In one paragraph

Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yue ZhangSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.

Haoni LuanSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.

Wenhan QiuSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.

Wei XuSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.

Wei FengSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.

Fei WangSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China.

Peng SongSchool of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng, China. songpeng@lcu.edu.cn.

Funding

Natural Science Foundation of Shandong Province,China ZR2022MC159

6 · The paper itself

Abstract

Bilirubin, a heme-derived metabolite with pronounced bioactivity, exhibits significant potential for pharmaceutical applications. This study developed a recombinant Escherichia coli-based biliverdin biotransformation system, enabling efficient bilirubin synthesis via heterologous expression of a novel biliverdin reductase (BvdR', XP_032760038.1) from Rattus norvegicus and a glucose dehydrogenase (GDH) from Priestia megaterium. Under optimized conditions (520 mg/L biliverdin, pH 7.5, 37 °C), the system achieved a biliverdin conversion rate of 99.2% and a bilirubin yield of 89.9%. The integration of an NADPH in situ regeneration system significantly reduced synthesis costs, providing a novel strategy for scalable bilirubin production.

Indexed as

BilirubinBiliverdineEscherichia coliAnimalsBiotransformationGlucose 1-DehydrogenaseNADPOxidoreductases Acting on CH-CH Group DonorsRatsRecombinant ProteinsBilirubinBiliverdinebiliverdin reductaseGlucose 1-DehydrogenaseNADPOxidoreductases Acting on CH-CH Group DonorsRecombinant ProteinsBilirubinBiliverdinBiliverdin reductaseBiosynthesisCoenzyme regeneration

Identifiers

PMID40856945

DOI10.1007/s11274-025-04527-z

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.